Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

End Of Aranesp, Procrit Pricing War Illustrates Inflationary Impact Of ASP

Executive Summary

Pricing constraints created by changes in Medicare Part B reimbursement may mean that segment growth will be the key driver for erythropoietin products going forward

You may also be interested in...



Avastin For Lung Cancer Will Be Free To Patients Who Beat The Average

Under a Genentech program that caps expenditures for Avastin, the oncologic will be free of charge to patients who continue using the therapy beyond the median duration of treatment for lung cancer

Avastin For Lung Cancer Will Be Free To Patients Who Beat The Average

Under a Genentech program that caps expenditures for Avastin, the oncologic will be free of charge to patients who continue using the therapy beyond the median duration of treatment for lung cancer

Private Payers Beginning To Adopt ASP-Based Reimbursement, Amgen Says

Private payers are beginning to adopt Medicare's average sales price-based methodology for drugs administered in the physician's office, Amgen said during a quarterly earnings call April 19

Related Content

UsernamePublicRestriction

Register

PS046855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel